?The interaction of ph sensitive liposomes with lung surfactant in monolayer biomimetic systems?

MARIA JULIA ALTUBE; ANDREA C. CUTRÓ; ANIBAL E. DISALVO; ROMERO, EDER L.

Tucuman

Congreso; XLV Reunión Anual Sociedad Argentina de Biofísica 2016; 2016

SAB. Sociedad argentina de Biofísica

investigación y Transferencia de Santiago del Estero, Santiago del Estero, ArgentinaThe archaeosomes (ARC) are lipid vesicles made of total polar archaeolipids (TPA) extracted from hyperhalopile archaebacteria (1). Previous studies have shown that ARC are more extensively captured by alveolar macrophages and lung epithelial cells in vitro than conventional liposomes (2). This makes ARC excellent candidates for delivering drugs to the lungs. Although, in an in vivo context inhaled ARC must first interact with the pulmonary surfactant (PS) lining layer that covers the internal surface of the alveolus and provides the low surface tension at the air-liquid interface that is necessary to prevent collapse during expiration. Interactions with the PS film determine the subsequent retention or translocation of the inhaled ARC and hence their potential activity on target cells (3). In order to evaluate the effect of the interaction of ARC, the changes in surface pressure (π) and compressibility produced in lung surfactant monolayers by ARC addition were studied. The results show that ARC increases the π, indicating its incorporation which is dependent of the membrane packing because the Δπ observed at high surface pressure (40 mN/m) are negligible in comparison to those obtained at low surface pressure (10 mN/m), (Δπ=4.5 mN/m). Besides, the ARC concentration is crucial to produce changes in pressure monolayers, at low concentration (0.3 µg/ mL) no significant changes were observed. Moreover, the ARC incorporation rates into the membrane was substantially affected if the addition done onto the monolayer in comparison to that in the subphase being the first much higher than the second.(1)Gonzalez, R.O., Higa,L. H., Cutrullis, R.A., Bilen, M., Morelli, I., Roncaglia, D.I., & Romero, E.L. (2009). BMC biotechnology, 9(1), 71.(2)Altube, M.J., Selzer, S.M., de Farias, M.A., Portugal, R.V., Morilla, M.J., Romero, E.L. (2016). Nanomedicine, 11(16):2103-17. (3)Gehr, P., & Tsuda, A. (2014). Nanoparticles in the Lung: Environmental Exposure and Drug Delivery, 21.